CONTACT-02: Final OS Results of Cabo/Atezo Versus Second Novel Hormonal Therapy for mCRPC

The final overall survival (OS) results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabozantinib plus atezolizumab (cabo/atezo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Neeraj Agarwal presented these results as a late-breaking abstract at the European Society for Medical Oncology Congress 2024.

CONTACT-02 enrolled 575 patients with mCRPC, 289 to a cabo/atezo arm and the other 286 to a NHT arm. All patients had previously experienced disease progression on one prior NHT and had measurable extrapelvic nodal or visceral disease. The dual primary endpoints were progression-free survival (PFS) and OS.

Previous readouts of CONTACT-02 suggest that cabo/atezo significantly prolong PFS compared to novel hormonal therapy (NHT) in patients with mCRPC (HR, 0.65; 95% CI 0.50-0.84; P=.0007).

After a median follow-up of 24.0 months, the median OS was numerically higher but not statistically significant for cabo/atezo (HR, 0.89; 95% CI, 0.72-1.10; P=.296).

Improvement in OS was noted in multiple clinical subgroups, including patients with bone metastases (HR, 0.79; 95% CI, 0.63-1.00; P=.046) or liver metastases (HR, 0.68; 95% CI, 0.47-1.00; P=.051).

Dr. Agarwal noted that grade 3/4 treatment-related adverse events (TRAEs) occurred in 40% of the cabo/atezo study arm and 8% of the NHT arm. No grade 5 TRAEs were reported, and TRAEs led to discontinuation of all treatment in 17% and 15% of patients, respectively.

“Collectively, the results from the CONTACT-02 trial suggest that there are patients who could benefit from cabozantinib in combination with atezolizumab and that this regimen could be a valuable addition to the treatment landscape for patients with advanced prostate cancer,” said Amy Peterson, MD, Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, in a press release.